ArticleDie Ophthalmologie2025
[Characterization of periocular basal cell carcinoma in patients ≤ 50 years from 1996-2024 : A retrospective analysis at a university eye clinic].
Article in Die Ophthalmologie, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundBasal cell carcinoma (BCC) is rare in patients ≤ 50 years and can be associated with tumor predisposition syndromes (TPDS). The BAP1-TPDS is particularly relevant for ophthalmologists as it is associated with other malignant nonocular tumors.
objectiveRetrospective analysis of patients ≤ 50 years with periocular BCC with respect to demographic, clinical and histological features for the identification of TPDS including BAP1 staining as a possible screening procedure for BAP1-TPDS. MATERIAL AND
methodsIdentification of all patients ≤ 50 years with histologically confirmed BCC surgically treated at this hospital in the period 1996-2024. Documentation of the localization and histological subtype as well as evaluation of the immunohistochemical BAP1 staining.
resultsDuring the observational period 38 patients ≤ 50 years with a BCC of the ocular adnexa were identified including 5 patients with multiple BCC. The average age of the patients at the time of excision was 42.7 years. The histological growth pattern was predominantly nodular (89%) and the localization of the tumors was in decreasing order the lower eyelid (53%), medial eyelid angle (26%) and upper eyelid (21%). Of the patients two had a TPDS (Gorlin-Goltz syndrome and xeroderma pigmentosum). The majority of the tumors examined showed a clear BAP1 staining reaction (89%), A proportion of positive tumor cells below 25% was present in only 4 patients.
conclusionIn the case of patients ≤ 50 years with BCC or with other tumor entities, a TPDS should be considered. The BAP1 staining is interesting in this respect as it could represent an economically favorable screening method for a BAP1-TPDS and is possible without any substantial increase in labor costs.
Indexed as
Identifiers
40768037What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.